1. Cytotoxicity evaluation of curcumin treatment in DH82 canine histiocytic sarcoma cell line
- Author
-
Mozart Marins, Gabriel da Silva, Ana Lúcia Fachin, and Natália Yumi Noronha
- Subjects
Cell growth ,business.industry ,Cancer ,General Medicine ,medicine.disease ,Bioinformatics ,General Biochemistry, Genetics and Molecular Biology ,chemistry.chemical_compound ,chemistry ,Cell culture ,Canine Histiocytic Sarcoma ,Poster Presentation ,DNA methylation ,medicine ,Cancer research ,Curcumin ,Epigenetics ,Cytotoxicity ,business - Abstract
Background The identification of targets and new drugs to fight cancer is one the greatest challenges for Biotechnology researchers. Not only humans, but also animals are affected by this disease. It is estimated for example that one in every 3-4 dogs will develop some type of cancer during its lifetime, twice as much as the human being [1,2]. DNA methylation is an important epigenetic mechanism which control gene expression during cell proliferation and differentiation. Deregulation of this mechanism is one of the events which can contribute to the development of cancer [3]. The identification of epigenetic drugs, which are molecules that can revert aberrant DNA methylation, is one of the main areas of cancer research nowadays. In this regard, natural products are a rich source of possibilities to increase the arsenal of epigenetic drugs [1]. This study aims to analyze the cytotoxicity effect of curcumin treatments in DH82 canine histiocytic sarcoma cell line. This polyphenol derived from Curcuma longa has emerged as a potent multimodal cancer-preventing agent which modulates multiple cell signaling pathways and also been described as an inhibitor of DNA methylation[4]. The knowledge of the biological effects of these substances can pinpoint targets for the development of epigenetic drugs, with a positive impact for the treatment of canine and human cancer.
- Published
- 2014